Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Michael James Burke MD

Michael James Burke MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology

Member of the Cancer Center


  • Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. (Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM) Pediatr Blood Cancer 2015 May;62(5):743-50 PMID 25307519
  • How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. (Burke MJ) Future Oncol 2014 Dec;10(16):2615-27 PMID 24983955
  • A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. (Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS) Am J Hematol 2014 Sep;89(9):889-95 PMID 24891274
  • Epigenetic modifications in pediatric acute lymphoblastic leukemia. (Burke MJ, Bhatla T) Front Pediatr 2014;2:42 PMID 24860797
  • A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). (Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ) Bone Marrow Transplant 2014 Mar;49(3):440-2 PMID 24317126
  • Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR) Bone Marrow Transplant 2014 Feb;49(2):174-8 PMID 24185590
  • Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. (Pratt JA, Stricherz MK, Verghese PS, Burke MJ) Pediatr Blood Cancer 2014 Feb;61(2):366-8 PMID 24038944
  • How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. (Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C) Am J Hematol 2013 Sep;88(9):826-7 PMID 23737091
  • Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. (Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR) Biol Blood Marrow Transplant 2013 Jul;19(7):1021-5 PMID 23567175
  • Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. (Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR) Pediatr Blood Cancer 2013 Apr;60(4):705-10 PMID 23152304
  • Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR) Biol Blood Marrow Transplant 2013 Jan;19(1):138-42 PMID 22960388
  • Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. (Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL) Blood 2012 May 31;119(22):5201-10 PMID 22496163
  • Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8 PMID 22430088
  • Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. (Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2012 Jun;18(6):930-6 PMID 22108570
  • Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. (Burke MJ, Lindgen B, Verneris MR) Pediatr Blood Cancer 2012 Jun;58(6):840-5 PMID 21796765
  • Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3 PMID 21403127
  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. (Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ) Bone Marrow Transplant 2011 Jul;46(7):950-5 PMID 20856210
  • Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. (Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2011 Jun;17(6):831-40 PMID 20831896
  • Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. (Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2011 Mar;46(3):368-71 PMID 20548337
  • Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. (Verneris MR, Burke MJ) Curr Hematol Malig Rep 2010 Jul;5(3):157-62 PMID 20446122
  • Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. (Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM) Biol Blood Marrow Transplant 2010 Sep;16(9):1237-44 PMID 20302960
  • Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. (Beck JC, Burke MJ, Tolar J) Pediatr Blood Cancer 2010 Mar;54(3):490-1 PMID 19908296
  • Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 PMID 19731318
  • Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. (Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE) Blood 2009 Nov 5;114(19):4293-9 PMID 19706886
  • The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5 PMID 19621426
  • Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 PMID 19204709
  • Treatment of a CNS relapse while on therapy for Burkitt lymphoma. (Burke MJ, Dayton V) Pediatr Blood Cancer 2009 Feb;52(2):290-2 PMID 18937319
  • Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 PMID 18776928
  • Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 PMID 17417796
  • Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. (Burke MJ, Cohn SL) Pediatr Blood Cancer 2008 Mar;50(3):679-80 PMID 16900484
  • Last update: 04/21/2015